Literature DB >> 12161410

Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex.

Sazini Nzula1, Peter Vandamme, John R W Govan.   

Abstract

The Burkholderia cepacia complex is a diverse group of human pathogens that cause life-threatening lung infections in patients with cystic fibrosis or chronic granulomatous disease, and in patients requiring intensive care. Most previous antimicrobial susceptibility studies of these bacteria were performed before recent major revisions in the taxonomy of these bacteria. We determined the in vitro susceptibility of 65 B. cepacia complex isolates from clinical and environmental sources, representing six genomovars. Although intrinsic resistance is considered to be a common feature of the B. cepacia complex, MICs of individual antimicrobials varied widely and resistance was not exhibited by all members of the group.

Entities:  

Mesh:

Year:  2002        PMID: 12161410     DOI: 10.1093/jac/dkf137

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  44 in total

Review 1.  A decade of Burkholderia cenocepacia virulence determinant research.

Authors:  Slade A Loutet; Miguel A Valvano
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

Review 2.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

3.  Identification of hopanoid biosynthesis genes involved in polymyxin resistance in Burkholderia multivorans.

Authors:  Rebecca J Malott; Barbara R Steen-Kinnaird; Tracy D Lee; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

4.  Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.

Authors:  Juyan Zhou; Yunhua Chen; Setareh Tabibi; Luis Alba; Elizabeth Garber; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

5.  Biocide susceptibility of the Burkholderia cepacia complex.

Authors:  Helen Rose; Adam Baldwin; Christopher G Dowson; Eshwar Mahenthiralingam
Journal:  J Antimicrob Chemother       Date:  2009-01-18       Impact factor: 5.790

6.  Expression and characterization of penicillin-binding proteins in Burkholderia cenocepacia.

Authors:  Kimberly Musa Specht; Kyle H Sheetz; Courtney M Alexander; Lilian T Lamech; Lauren H O'Connor; Dawn M Walker; Hilary P Stevenson
Journal:  Curr Microbiol       Date:  2009-11-19       Impact factor: 2.188

7.  Burkholderia cenocepacia J2315 escapes to the cytosol and actively subverts autophagy in human macrophages.

Authors:  Souhaila Al-Khodor; Kimberly Marshall-Batty; Vinod Nair; Li Ding; David E Greenberg; Iain D C Fraser
Journal:  Cell Microbiol       Date:  2013-11-06       Impact factor: 3.715

8.  In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

9.  Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.

Authors:  Laurent Poirel; José-Manuel Rodriguez-Martinez; Patrick Plésiat; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Short Palate, Lung, and Nasal Epithelial Clone 1 Has Antimicrobial and Antibiofilm Activities against the Burkholderia cepacia Complex.

Authors:  Saira Ahmad; Jean Tyrrell; William G Walton; Ashutosh Tripathy; Matthew R Redinbo; Robert Tarran
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.